Keymed Biosciences Inc. (HKG:2162)

Keymed Biosciences Ratios and Metrics

Market cap in millions HKD. Fiscal year is January - December.

Fiscal Year	Current	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Jul 28, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Market Capitalization	18,589	8,516	13,586	14,174	9,651	-
Market Cap Growth	-37.32%	-37.32%	-4.15%	46.87%	-	-
Enterprise Value	17,098	6,555	10,725	10,331	15,170	-
Last Close Price	63.10	30.90	49.10	51.00	34.50	-
PS Ratio	40.80	18.69	34.83	125.30	71.30	-
PB Ratio	7.06	3.23	4.13	3.76	2.16	-
P/TBV Ratio	7.09	3.25	4.13	3.76	2.15	-
EV/Sales Ratio	37.53	14.39	27.49	91.33	112.08	-
Debt / Equity Ratio	0.30	0.30	0.14	0.04	0.01	-1.33
Asset Turnover	0.11	0.11	0.09	0.03	0.05	-
Inventory Turnover	0.13	0.13	0.66	0.07	1.02	-
Quick Ratio	3.04	3.04	8.80	8.45	31.55	4.42
Current Ratio	3.30	3.30	9.36	8.72	31.96	4.75
Return on Equity (ROE)	-18.85%	-18.85%	-11.31%	-8.69%	-305.24%	-
Return on Assets (ROA)	-10.23%	-10.23%	-7.32%	-8.65%	-10.09%	-15.67%
Return on Capital (ROIC)	-11.80%	-11.80%	-8.33%	-9.52%	-11.15%	-20.89%
Earnings Yield	-2.95%	-6.44%	-2.91%	-2.46%	-49.44%	-
FCF Yield	-5.71%	-12.46%	-5.53%	-5.43%	-4.92%	-
Buyback Yield / Dilution	-0.22%	-0.22%	-0.09%	-62.34%	-139.72%	-

Updated Sep 23, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.